The drug candidate – called vorasidenib – is a dual inhibitor of mutated IDH1 and IDH2, which is being developed for a hard-to-treat form of brain cancer called glioma. It was acquired by ...

Scientists from Adelaide and the United States have found a surprising connection between a rare type of arthritis and gene ...

The integration of targeted therapies into neuro-oncology is revolutionizing the management of primary CNS malignancies. Advances in sequencing technologies and the incorporation of molecular ...

The Phase 3 INDIGO Trial was presented in the 2023 ASCO Presidential Plenary session. Let’s hear the thoughts of some of the world’s leading glioma experts on the data from the study A ...